Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary Central Nervous System Lymphoma

Primary central nervous system lymphoma (PCNSL) harbors mutations that reinforce B cell receptor (BCR) signaling. Ibrutinib, a BTK inhibitor, targets BCR signaling and is particularly active in lymphomas with BCR and MYD88 mutations. We performed a proof of concept phase Ib study of ibrutinib monoth...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Cell
Main Authors: Lionakis, Michail S., Dunleavy, Kieron, Roschewski, Mark, Widemann, Brigitte C., Butman, John A., Schmitz, Roland, Cole, Diane E., Melani, Christopher, Higham, Christine S., Desai, Jigar V., Ceribelli, Michele, Chen, Lu, Thomas, Craig J., Little, Richard F., Gea-Banacloche, Juan, Bhaumik, Sucharita, Stetler-Stevenson, Maryalice, Pittaluga, Stefania, Jaffe, Elaine S., Heiss, John, Lucas, Nicole, Steinberg, Seth M., Staudt, Louis M., Wilson, Wyndham H.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5571650/
https://ncbi.nlm.nih.gov/pubmed/28552327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2017.04.012
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares